GO:0061760 antifungal innate immune response: Defense Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061760 antifungal innate immune response is a biological process that defends against fungi through germline-encoded innate immune mechanisms.
• Key cell types include macrophages, neutrophils, dendritic cells, and innate lymphoid cells that directly recognize fungal cell wall components.
• Pattern recognition receptors such as Dectin-1, Dectin-2, Mannose Receptor, and TLRs detect fungal pathogen-associated molecular patterns and trigger antifungal effector functions.
• Effector mechanisms include phagocytosis, oxidative burst, neutrophil extracellular trap formation, and secretion of antifungal peptides and cytokines.
• Dysregulation of this response contributes to invasive fungal infections such as aspergillosis, candidiasis, and mucormycosis, especially in immunocompromised patients.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal dissection of genes involved in antifungal innate immunity and support drug discovery.
Description
The antifungal innate immune response (GO:0061760) is a biological process defined as a defense response against a fungus mediated through an innate immune response, which relies on germline-encoded components that directly recognize pathogen components. This process is the first line of host defense against fungal pathogens and is essential for controlling infections caused by Candida, Aspergillus, Cryptococcus, and other fungi. Unlike adaptive immunity, innate antifungal responses are rapid and broadly conserved, involving cellular and humoral arms that together limit fungal burden and shape subsequent adaptive responses. Researchers study GO:0061760 to understand host-pathogen interactions, identify therapeutic targets, and develop immunotherapies for invasive fungal diseases. The rising incidence of antifungal resistance and the limited arsenal of antifungal drugs underscore the need for deeper mechanistic insights into innate immunity. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of the antifungal innate immune response, its molecular players, disease relevance, and experimental models for investigation.
antifungal innate immune response At A Glance
| GO ID | GO:0061760 |
|---|---|
| GO term | antifungal innate immune response |
| Ontology | biological_process |
| Synonym | None |
| Major function | Defense response against fungi mediated by germline-encoded innate immune components |
| Key cell types | Macrophages, neutrophils, dendritic cells, innate lymphoid cells |
| Key receptors | Dectin-1, Dectin-2, Mannose Receptor, TLR2, TLR4, complement receptor 3 |
| Effector mechanisms | Phagocytosis, oxidative burst, NET formation, cytokine and antimicrobial peptide secretion |
| Disease relevance | Invasive aspergillosis, candidiasis, mucormycosis, and other fungal infections |
What Is GO:0061760?
In our own words, GO:0061760 describes the coordinated set of innate immune reactions that a host mounts against a fungus. It encompasses recognition of fungal pathogen-associated molecular patterns by germline-encoded receptors, activation of signaling cascades, and execution of effector functions such as phagocytosis, production of reactive oxygen species, release of antimicrobial peptides, and cytokine-mediated inflammation. This process is distinct from adaptive antifungal immunity because it does not require somatic recombination or immunological memory; instead, it depends on invariant receptors and rapidly deployable effector mechanisms.
Why Is antifungal innate immune response Important in Cell Biology?
Understanding GO:0061760 is critical because invasive fungal infections cause substantial morbidity and mortality, particularly in immunocompromised individuals, and current antifungal therapies are limited by toxicity, drug interactions, and emerging resistance. The innate immune response determines the outcome of host-fungus encounters and offers targets for host-directed immunotherapies. Moreover, mechanistic knowledge of this process informs vaccine development, biomarker discovery, and personalized risk stratification in patients with hematologic malignancies, transplant recipients, and critical illness.
• Provides first-line defense against opportunistic fungal pathogens such as Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans.
• Shapes the adaptive immune response by modulating antigen presentation and cytokine milieu.
• Dysregulation leads to invasive fungal infections in immunocompromised patients.
• Fungal biofilms and resistance mechanisms can evade innate immunity, complicating treatment.
• Innate lymphoid cells contribute to antifungal immunity at mucosal barriers.
• Antifungal peptides from the host immune response are being explored as novel therapeutics.
• Genetic defects in innate immune pathways (e.g., CARD9 deficiency) increase susceptibility to fungal diseases.
• Modeling with CRISPR enables identification of host factors that restrict or promote fungal growth.
• Understanding species-specific immune evasion by Candida auris informs infection control.
• The process is conserved across plants and animals, with plant defensins illustrating ancient antifungal mechanisms.
What Happens During antifungal innate immune response?
Recognition of fungal pathogen-associated molecular patterns
In simple terms: The immune system spots molecules on the surface of fungi that are not present on human cells.
Innate immune cells express pattern recognition receptors (PRRs) that detect fungal cell wall components such as beta-glucans, mannans, and chitin. Dectin-1 recognizes beta-1,3-glucan, while Dectin-2 and Mannose Receptor bind mannans; TLR2 and TLR4 also contribute to fungal sensing. This recognition triggers intracellular signaling through Syk-CARD9, NF-kB, and inflammasome pathways, leading to cytokine production and effector activation. In Candida auris, specific PRR engagement influences phagocytosis and killing efficiency.
Activation of innate immune cells and signaling cascades
In simple terms: Once fungi are detected, immune cells switch on genes that help them attack.
Ligation of PRRs activates kinases such as Syk and PKC-delta, leading to CARD9-BCL10-MALT1 complex assembly and NF-kB activation. This induces transcription of proinflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and chemokines that recruit neutrophils and monocytes to infection sites. Inflammasome activation by fungal components leads to IL-1beta maturation, which is critical for protective antifungal immunity. Innate lymphoid cells (ILCs) also respond to fungal signals by producing cytokines that orchestrate tissue-specific defense.
Effector mechanisms: phagocytosis and oxidative burst
In simple terms: Immune cells engulf fungi and release toxic chemicals to kill them.
Macrophages and neutrophils phagocytose fungal cells through complement receptor 3 and Fc receptors, followed by phagosome maturation and fusion with lysosomes. The NADPH oxidase complex produces reactive oxygen species (ROS) in a process called oxidative burst, which is essential for killing Candida and Aspergillus. Neutrophils also release neutrophil extracellular traps (NETs) composed of DNA and antimicrobial proteins that immobilize and damage fungal hyphae. Defects in these effector mechanisms, as seen in chronic granulomatous disease, predispose to fungal infections.
Secretion of antifungal peptides and cytokines
In simple terms: Immune cells release small proteins that directly attack fungi and call for backup.
Antimicrobial peptides such as defensins, cathelicidins, and histatins are secreted by epithelial cells and phagocytes and exhibit direct antifungal activity by disrupting fungal membranes. Plant defensins illustrate the ancient evolutionary origin of such peptides. Cytokines like GM-CSF, IFN-gamma, and IL-17 promote neutrophil recruitment and activation, enhancing fungal clearance. Dysregulated cytokine production can lead to immunopathology, highlighting the need for balanced responses.
Resolution and shaping of adaptive immunity
In simple terms: After the initial attack, the immune system dials down inflammation and remembers the fungus.
Following fungal clearance, anti-inflammatory mechanisms limit tissue damage and promote resolution. Dendritic cells that have phagocytosed fungi migrate to lymph nodes and present antigens to T cells, linking innate recognition to adaptive Th1 and Th17 responses. This bridge is essential for long-term protective immunity and vaccine development. In chronic fungal infections such as aspergillosis, persistent innate activation can lead to fibrosis and tissue remodeling.
Key Genes Involved in GO:0061760 antifungal innate immune response
The following genes and proteins are central to the antifungal innate immune response and are frequently studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CLEC7A (Dectin-1) | Beta-glucan receptor; triggers Syk-CARD9 signaling | Polymorphisms linked to fungal susceptibility; target for immunomodulation |
| CLEC6A (Dectin-2) | Mannan receptor; activates NF-kB | Mediates cytokine responses to Candida and Aspergillus |
| CARD9 | Adaptor in PRR signaling; activates NF-kB | Deficiency causes invasive fungal infections; key host factor |
| TLR2 | Recognizes fungal phospholipomannan and zymosan | Modulates inflammatory response to fungi |
| TLR4 | Senses fungal mannans; induces proinflammatory cytokines | Contributes to Aspergillus recognition |
| MYD88 | Adaptor for TLR/IL-1R signaling | Essential for antifungal innate immunity in mice and humans |
| NLRP3 | Inflammasome sensor; activates caspase-1 and IL-1beta | Critical for protective anti-Candida immunity |
| IL1B | Proinflammatory cytokine; recruits neutrophils | Polymorphisms affect fungal infection outcomes |
| IL17A | Promotes neutrophil recruitment and antimicrobial peptide production | Key in mucosal antifungal defense |
| IFNG | Activates macrophages; enhances fungal killing | Used therapeutically in refractory fungal infections |
| CYBB (NOX2) | NADPH oxidase subunit; produces ROS | Defects cause chronic granulomatous disease with fungal susceptibility |
| MPO | Myeloperoxidase; generates hypochlorous acid | Polymorphisms influence Candida killing |
| DEFB1 | Beta-defensin; direct antifungal peptide | Expressed in epithelia; candidate for peptide therapeutics |
| CAMP (LL-37) | Cathelicidin; disrupts fungal membranes | Broad-spectrum antifungal activity; immunomodulatory |
| S100A8/A9 | Calcium-binding proteins; modulate inflammation | Biomarkers and effectors in fungal infections |
| CLEC4D (Mincle) | Senses fungal glycolipids | Induces TNF and IL-6; role in Candida immunity |
| ILC3 (RORgt+ ILCs) | Innate lymphoid cells producing IL-17/IL-22 | Critical for mucosal antifungal defense |
How Is antifungal innate immune response Regulated?
The antifungal innate immune response is tightly regulated at multiple levels to balance effective fungal clearance with avoidance of immunopathology. Positive regulators include CARD9-BCL10-MALT1 signaling downstream of Dectin-1/2, which amplifies NF-kB and MAPK activation. Negative regulation is mediated by inhibitory receptors such as CLEC12A and by phosphatases like SHP-1 that dampen Syk signaling. Cytokine signaling through IFN-gamma and GM-CSF primes phagocytes for enhanced killing, while IL-10 and TGF-beta limit excessive inflammation. Inflammasome activity is controlled by autophagy and by NLRP3 inhibitors, preventing IL-1beta overproduction. Additionally, metabolic reprogramming (e.g., HIF-1alpha) influences phagocyte function during fungal infection. These regulatory layers are potential targets for host-directed therapies.
antifungal innate immune response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CARD9 | Invasive fungal infections (candidiasis, aspergillosis) | Knockout mice or human iPSC-derived macrophages |
| CLEC7A (Dectin-1) | Susceptibility to mucocutaneous candidiasis | Point-mutation knock-in mice (Y238X) |
| CYBB (NOX2) | Chronic granulomatous disease with aspergillosis | Knockout neutrophils or iPSC-derived phagocytes |
| IL17A | Chronic mucocutaneous candidiasis | Knockout mice or T-cell-specific deletion |
| NLRP3 | Inflammasome-related fungal susceptibility | Knock-in mice expressing gain-of-function NLRP3 |
Invasive Aspergillosis
Invasive aspergillosis is a life-threatening fungal infection primarily affecting immunocompromised patients, such as those with neutropenia or undergoing hematopoietic stem cell transplantation. The innate immune response, particularly neutrophil-mediated killing and ROS production, is critical for controlling Aspergillus fumigatus. Defects in NADPH oxidase (chronic granulomatous disease) or corticosteroid therapy impair fungal clearance and increase susceptibility. Aspergillus biofilms further evade innate immunity and contribute to antifungal resistance. Research into GO:0061760 mechanisms has identified Dectin-1 and CARD9 as key host factors, suggesting potential targets for immunotherapy.
Candidiasis and Candida auris Infections
Candida species cause mucosal and systemic infections, with Candida auris emerging as a multidrug-resistant pathogen of global concern. Innate immune recognition of C. auris involves Dectin-1 and Mannose Receptor, but the fungus can evade phagocytosis and killing. Neutrophils and macrophages are essential for controlling candidiasis, and defects in oxidative burst or NET formation increase severity. IL-17-producing innate lymphoid cells (ILC3) are crucial for mucosal anti-Candida defense. Understanding these interactions is vital for developing new therapies against resistant Candida strains.
Mucormycosis
Mucormycosis is an angioinvasive fungal infection caused by Mucorales, with high mortality in immunocompromised hosts, especially those with diabetic ketoacidosis or hematologic malignancies. Innate immunity, particularly neutrophil function and iron metabolism, plays a central role in defense. Patients with defects in phagocyte function or those receiving deferoxamine are at increased risk. The rapid progression of mucormycosis underscores the importance of early innate immune activation and the need for improved immunotherapeutic strategies.
Fungal Infections in Primary Immunodeficiencies
Primary immunodeficiencies affecting the innate immune response, such as CARD9 deficiency, predispose to severe fungal infections including candidiasis and aspergillosis. Defects in the IL-17/IL-22 axis lead to chronic mucocutaneous candidiasis. These monogenic disorders provide insights into non-redundant pathways in GO:0061760 and guide genetic diagnosis and targeted therapy. Studying such patients has revealed critical roles for Dectin-1, CARD9, and inflammasome components in human antifungal immunity.
From antifungal innate immune response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CARD9 mediate protective anti-Candida immunity? | CARD9 knockout mouse or human macrophage cell line |
| What is the role of Dectin-1 Y238X polymorphism in fungal susceptibility? | Point-mutation knock-in mouse or CRISPR-edited human cells |
| Can overexpression of LL-37 enhance fungal killing? | Overexpression of CAMP in epithelial cell lines or mice |
| How does C. auris evade innate immune recognition? | CRISPR knockout of PRRs in human macrophages followed by infection |
| What is the contribution of ILC3 to mucosal antifungal defense? | RORgt+ ILC3 knockout or reporter mice |
| Does NOX2 deficiency impair Aspergillus killing? | CYBB knockout neutrophils or iPSC-derived phagocytes |
How to Study the antifungal innate immune response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Host genes affecting fungal survival | Identify novel antifungal immunity regulators |
| RNA-seq | Transcriptional changes during infection | Define gene expression programs in GO:0061760 |
| Proteomics | Protein abundance and modifications | Discover secreted antifungal peptides |
| Live-cell imaging | Phagocytosis and NET formation | Visualize effector mechanisms |
| ROS detection assay | Oxidative burst capacity | Assess neutrophil function |
| Fungal killing assay | CFU reduction | Quantify antimicrobial activity |
| Cytokine ELISA | Secreted cytokine levels | Measure inflammatory response |
| Mouse infection model | Survival and fungal burden | Validate therapeutic targets in vivo |
CRISPR-Cas9 Knockout Screens
Genome-wide CRISPR knockout screens in macrophage cell lines or primary cells can identify host genes that restrict or promote fungal growth. For example, knocking out candidate PRRs or signaling molecules followed by infection with Candida or Aspergillus reveals essential components of GO:0061760. These screens have uncovered novel regulators such as CARD9 and inflammasome components.
Transcriptomic and Proteomic Profiling
RNA-seq of innate immune cells challenged with fungi reveals transcriptional programs activated during the antifungal response, including cytokine and antimicrobial peptide genes. Proteomics can identify post-translational modifications and secreted effectors. Single-cell RNA-seq uncovers heterogeneity among responding cell populations, such as ILC3 subsets.
Imaging and Functional Assays
Live-cell imaging with fluorescent fungi allows real-time visualization of phagocytosis, phagosome maturation, and NET formation. ROS production can be measured by chemiluminescence or fluorescent probes. Fungal killing assays quantify CFU reduction after co-culture with phagocytes. These methods directly assess effector functions of GO:0061760.
Animal Models of Fungal Infection
Mouse models of systemic candidiasis, invasive aspergillosis, and mucormycosis are used to study innate immunity in vivo. Knockout mice lacking CARD9, Dectin-1, or IL-17A show increased fungal burden and mortality. These models are essential for validating therapeutic targets identified in vitro.
How CRISPR Can Be Used to Study GO:0061760 antifungal innate immune response
Knockout
CRISPR knockout of genes such as CARD9, CLEC7A, or CYBB in human macrophage cell lines or iPSC-derived phagocytes ablates specific innate immune pathways, allowing researchers to test their requirement for fungal killing and cytokine production. Knockout mice generated by CRISPR can model human immunodeficiencies and reveal non-redundant roles in GO:0061760.
Point Mutation
Point mutations identified in patients, such as Dectin-1 Y238X or CARD9 variants, can be introduced into cell lines or mice using CRISPR base editing or homology-directed repair to study their functional impact on antifungal immunity. These models help establish causality between genetic variants and susceptibility to fungal infections.
Knock-in
Knock-in of reporter tags (e.g., GFP) or epitope tags into endogenous loci enables tracking of protein expression and localization during fungal infection. Knock-in of human disease alleles into mouse models facilitates in vivo studies of GO:0061760.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of antifungal peptides such as LL-37 or defensins can enhance fungal killing and test their therapeutic potential. Overexpression of signaling molecules like CARD9 can amplify innate responses and reveal dose-dependent effects.
How EDITGENE Supports antifungal innate immune response Research
Researchers studying antifungal innate immune response-related genes often need to determine whether a candidate gene is causally involved in fungal recognition, signaling, or effector function. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and accelerating discovery in antifungal immunity.
Contact EDITGENE today to design your custom CRISPR model for antifungal innate immune response research.
Frequently Asked Questions About antifungal innate immune response
What is GO:0061760 antifungal innate immune response?
GO:0061760 is a Gene Ontology biological process term describing the defense response against fungi mediated by germline-encoded innate immune mechanisms, including recognition, signaling, and effector functions.
What genes are involved in antifungal innate immune response?
Key genes include CLEC7A (Dectin-1), CARD9, TLR2, TLR4, MYD88, NLRP3, IL1B, IL17A, IFNG, CYBB, and DEFB1, among others.
How does the innate immune system recognize fungi?
Pattern recognition receptors such as Dectin-1, Dectin-2, Mannose Receptor, and TLRs detect fungal cell wall components like beta-glucans and mannans, triggering signaling cascades.
What are the effector mechanisms of antifungal innate immunity?
Effector mechanisms include phagocytosis, oxidative burst, neutrophil extracellular trap formation, and secretion of antimicrobial peptides and cytokines.
Which diseases are associated with defects in antifungal innate immunity?
Defects can lead to invasive aspergillosis, candidiasis, mucormycosis, and chronic mucocutaneous candidiasis, especially in immunocompromised patients.
How can CRISPR be used to study antifungal innate immunity?
CRISPR knockout, knock-in, point mutation, and overexpression models allow functional dissection of genes involved in fungal recognition and killing.
What cell types are important for antifungal innate immune response?
Macrophages, neutrophils, dendritic cells, and innate lymphoid cells (ILCs) are critical for recognizing and eliminating fungi.
What is the role of CARD9 in antifungal immunity?
CARD9 is an adaptor protein downstream of Dectin-1/2 that activates NF-kB and is essential for protective antifungal responses; deficiency causes invasive fungal infections.
How do fungi evade innate immunity?
Fungi can evade innate immunity by masking cell wall components, forming biofilms, and modulating host signaling, as seen with Candida auris and Aspergillus fumigatus.
What model systems are used to study antifungal innate immunity?
Common models include mouse infection models, human macrophage cell lines, iPSC-derived phagocytes, and CRISPR-engineered cells.
Conclusion
The antifungal innate immune response (GO:0061760) is a vital biological process that protects hosts from fungal infections through coordinated recognition, signaling, and effector mechanisms. Dysregulation of this process contributes to severe fungal diseases, particularly in immunocompromised individuals. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of host factors and therapeutic targets. Continued research into GO:0061760 will inform the development of novel immunotherapies and improve outcomes for patients with invasive fungal infections.
References
- 1. Mercer DK et al.. 2020. Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.. Front Immunol 11:2177 PMID: 33072081
- 2. Wong SSW et al.. 2025. Antifungal Innate Immunity.. Adv Exp Med Biol 1476:225-250 PMID: 40622545
- 3. Wang Y et al.. 2022. Innate immune responses against the fungal pathogen Candida auris.. Nat Commun 13(1):3553 PMID: 35729111
- 4. Yin X et al.. 2023. [Function of innate lymphoid cells in the antifungal immune response].. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 39(11):1044-1048 PMID: 37980557
- 5. Segal BH. 2009. Aspergillosis.. N Engl J Med 360(18):1870-84 PMID: 19403905
- 6. Kashyap VH et al.. 2023. Exploring the intersection of Aspergillus fumigatus biofilms, infections, immune response and antifungal resistance.. Mycoses 66(9):737-754 PMID: 37212186
- 7. Hamilos G et al.. 2011. Pulmonary mucormycosis.. Semin Respir Crit Care Med 32(6):693-702 PMID: 22167397
- 8. Thomma BP et al.. 2002. Plant defensins.. Planta 216(2):193-202 PMID: 12447532
